Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JALSG-PhALL219 dasatinib-to-ponatinib response-adapted study in newly diagnosed Ph-positive ALL
jRCTs041190096Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jan 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib, ponatinib and prednisolone in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia and acute lymphoblastic leukemia (ALL), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: 3-year event-free survival rate. Started Jan 2020; status: active, not recruiting.
02
Drugs
dasatinibponatinibprednisolone
03
Conditions
Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemiaacute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCTs041190096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041190096.